B Activation in Alveolar Macrophages
Requires I B kinase- , but Not Nuclear Factor- B
Inducing Kinase
|
| |
ABSTRACT |
|---|
|
|
|---|
Cytokine mediated activation of alveolar macrophages (AMs) is an
important event in the pathogenesis of fibrosing alveolitis (FA).
Through membrane-associated antigens, cytokines (e.g., tumor necrosis-factor-
and interleukin-1) are believed to activate a
common kinase cascade that initiates the cytoplasmic degradation of I
B and nuclear translocation of "nuclear factor-
B" (NF-
B). In
the nucleus, NF-
B promotes the transcription of genes encoding chemokines and cytokines involved in chronic inflammation. Preventing cytokine-mediated NF-
B activation is a potential strategy
for attenuating the lung injury that occurs in FA. Previously, we have demonstrated that, unlike AMs from healthy volunteers, AMs from patients with inflammatory lung diseases express the coxsackie/adenovirus receptor and the
v integrins required for adenovirus (Adv) infection. This property allows Adv-mediated transgene delivery to diseased, but not normal, AMs and analysis of
molecular pathways involved in gene transcription. In this study,
AMs were infected with Adv constructs expressing a defective
subunit of I
B kinase (AdvIKK
kd) and a defective NF-
B inducing
kinase (AdvNIKkd) to investigate the contribution of these molecules to NF-
B activation. We observed that IKK
, but not NIK,
was required for NF-
B activation. The results of this study identify
IKK
, but not NIK, as a potential therapeutic target in diseases
that involve NF-
B-dependent gene transcription.
| |
INTRODUCTION |
|---|
|
|
|---|
Keywords: fibrosing alveolitis; NF-
B; gene transcription; pulmonary
inflammation
Fibrosing alveolitis (FA) is a chronic inflammatory process involving the pulmonary interstitium and alveoli, resulting in excessive collagen deposition and impaired organ function. The current understanding of disease pathogenesis envisages that FA is initiated by alveolar epithelial and/or capillary endothelial cell injury by inhaled particles (e.g., asbestos), physical injury (e.g., radiation), or antigens that are deposited in the pulmonary vasculature (e.g., drugs like bleomycin, amiodarone, or nitrofurantoin) (1-3). Frequently, an initiating antigen is not identified, and the term "cryptogenic fibrosing alveolitis" is applied to the disease. These diverse antigens trigger a common inflammatory process through cytokine, chemokine, and adhesion molecule production by alveolar macrophages (AMs) and other immune effector cells within the lung. Chemokines and adhesion molecules recruit monocytes, neutrophils, and eosinophils to the lower airway, while cytokines amplify lung injury through the activation of these cells and fibroblasts that deposit collagen (4, 5). The disease process is frequently progressive, resulting in a five year mortality of 50% and chronic respiratory morbidity in many survivors (6). The failure of existing therapies to significantly improve survival highlights the need for new treatment strategies.
There are two lines of evidence to support the hypothesis
that NF-
B activation is a critical event in the pathogenesis of FA. First, NF-
B activation is required for the expression of cytokines (e.g., tumor necrosis-factor [TNF]-
, interleukin [IL]-6), chemokines (e.g., IL-8), and critical enzyme systems (e.g., nitric oxide synthetase) that earlier studies have determined to be important in the pathogenesis of FA (7, 8). Second, there is now
data from animal models directly linking nuclear factor-
B
(NF-
B) activation to the pathogenesis of FA, which contrast
the low basal levels of NF-
B activity in normal AMs (9) with
the increased activity of the transcription factor in AMs and respiratory epithelial cells of rats with FA (10, 11). It has been
proposed that selective inhibition of molecular pathways that
regulate NF-
B activation may be a future therapeutic strategy
in FA and other chronic inflammatory lung diseases, including
chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) (12, 13).
The cytoplasmic binding of NF-
B to I
B proteins prevents
gene transcription under resting conditions (14, 15). A kinase cascade that regulates I
B degradation through phosphorylation of two N-terminal serine residues activates NF-
B-dependent gene transcription (16). I
B phosphorylation allows recognition of the protein by a specialized E3 ubiquitin ligase
complex (E3I
B) that ubiquinates lysine residues, targeting the
molecule for degradation by the 26S proteosome (17, 18). Once
free of I
B, NF-
B is free to translocate into the nucleus and
activate gene transcription. Serine phosphorylation is the only
regulated step of I
B degradation (19), identifying this process
as a potential target for antiinflammatory therapies.
Numerous studies involving cell lines and transgenic mice
suggest that TNF-
and IL-1 degrade I
B though a common
kinase cascade (20-29). Binding of TNF-
to the type 1 receptor (TNFR1) recruits the receptor-associated antigens, TNF
receptor-associated death domain protein (TRADD), TNFR-associated factor-2 (TRAF-2), and receptor-interacting protein (RIP) to the cell surface. Similarly, binding of IL-1 to its
type 1 receptor (IL-1R1) and receptor accessory protein (AcP)
facilitates an interaction between IL-1 receptor-associated kinase (IRAK) and TRAF-6. Both sets of receptor-associated
proteins form an active signaling complex that binds to NF-
B-inducing kinase (NIK). The requirement for NIK in TNF-
and IL-1 mediated NF-
B activation was established by Malinin and colleagues, when over-expression of kinase defective
NIK in a 293-human embryonic kidney (EBNA) cell line was
shown to inhibit nuclear activity of the transcription factor (20).
NIK itself does not directly phosphorylate I
B, but rather activates an intermediate "I
B kinase" (IKK) complex that performs this function (21, 22). IKK is composed of two structural
proteins, IKK
(or NEMO) and IKK complex-associated protein (IKAP) and two catalytic subunits (IKK
and IKK
), the functions of which have been largely determined using cell
lines and knock-out mice (23-25, 27). Over-expression of catalytic subunits in cell lines indicates that IKK
, but not IKK
,
is required for TNF-
and IL-1 mediated I
B degradation.
The death of IKK
knock out (IKK
/
) mice in utero of
hepatocyte apoptosis, due to the absence of TNF-
-induced
NF-
B activation, provides further evidence that IKK
is critical for cytokine mediated NF-
B activation (25). The function of IKK
is less clear, but based on studies involving IKK
/
mice, it is likely to regulate NF-
B activity during
cellular differentiation (26).
Although studies involving IKK
/
mice have provided
important information concerning the function of the IKK
complex, the role of NIK is less certain. Recent studies involving transgenic mice that express a defective NIK with a mutation at the TRAF2 interacting site ("aly/aly mice") suggest
that, at least within murine cells, NIK may be only selectively
required for lymphotoxin and not TNF-
or IL-1-mediated
NF-
B activation (30-32). Furthermore, we have previously
demonstrated that other stimuli, also likely to be involved in
the activation of AMs that occurs in FA, result in proinflammatory gene transcription independent of NF-
B (33, 34).
Taken together, this evidence suggests that the existing model
of NIK function, derived from studies involving transformed cell lines, may not be applicable to fully differentiated primary macrophages. Before selective inhibition of proinflammatory
gene transcription can be considered as a therapeutic option
in pulmonary disease, the mechanism of NF-
B activation that
operates in primary human AMs will need to be determined.
In particular, defining the point at which TNF-
and IL-1-
responsive kinase cascades converge, as inhibition of the pathways before this point is unlikely to influence NF-
B dependent gene expression in vivo.
Recently, we demonstrated successful in vitro delivery of
Adv transgenes to AMs obtained from patients with fibrotic
lung disease, but not from normal volunteers (35). The differential transgene expression is related to upregulation on diseased AMs of the CAR,
v
3, and
v
5 integrins that are required for Adv infection (36, 37). The purpose of this study
was to exploit this property of diseased AMs to deliver transgenes encoding components of the kinase cascade, believed to
regulate NF-
B activation, to investigate the disease-specific
mechanisms of proinflammatory gene transcription in FA.
Substitution of 429/430 lysine for alanine within the ATP
binding site of the NIK molecule (NIKkd) and substitution of
alanine 44 for arginine within the kinase domain of the IKK
subunit (IKK
kd) produces proteins previously determined
to be kinase-defective when expressed in both primary cells
and transformed cell lines (20, 38, 39). Using Adv constructs
encoding these kinase defective proteins (AdvIKK
kd and
AdvNIKkd), we determined that constitutive and cytokine
mediated NF-
B activation and IL-6 production requires IKK
,
but not NIK. This study provides evidence that functionally
important IKK kinases, other than NIK, contribute to constitutive and cytokine induced NF-
B activation in primary human
macrophages. These findings suggest that therapies targeting components of the kinase cascade above IKK
are unlikely to
effectively inhibit proinflammatory gene transcription.
| |
METHODS |
|---|
|
|
|---|
Cells
BALs were obtained from patients undergoing diagnostic bronchoscopy for suspected FA (40). For inclusion, patients were required to fulfill the criteria for the diagnosis of cryptogenic FA (41). BALs were collected in a siliconized media bottle, centrifuged (1,500 rpm for 10 minutes), washed, and resuspended in serum free Roswell Park Memorial Institute medium (RPMI) (5 × 106 cells/ml). An enriched AM population was obtained using magnetic polystirene beads coated with mAb to CD2 (Dynal CD2 CELLection kit; Dynal, Bromborough, UK). Beads were added at five times the number of alveolar T cells calculated by haemocytometer and incubated for 30 minutes on a rotator before transfer onto a magnetic particle concentrator (Dynal) for 3 minutes to facilitate attachment of the rosetted T cells to the test tube wall. The fluid containing the negatively selected AMs was then aspirated. BALs processed using this technique were routinely determined to contain more than 97% AMs by fluorescence activated cell sorter (FACS) analysis.
Adv Constructs
Adv constructs were generated according to the protocol described by
He and colleagues (42). Constructs encoded wild-type (wt) and kinase
defective (kd) NIK, (AdvNIKwt and AdvNIKkd; Prof Liellach, Weizmann Institute, Givatoyim, Israel), a "Green Fluorescent Protein" (GFP)
reporter (AdvGFP; Dr Mahon, KIR, London, UK), an IKK
kd, and
porcine I
B
(AdvIKK
kd and AdvI
B
; Dr de Martin, Vienna,
Austria). A FLAG tag was incorporated into the IKK
kd, NIKwt,
and NIKkd genes. Substitution of alanine 44 for arginine within the
IKK
kinase domain, and lysine 429/430 for alanine within the NIK
ATP binding site, produced kinase-defective proteins (20, 38). Porcine I
B
has more than 95% homology with the human molecule
and associates with human NF-
B (43). Constructs were propagated
in 293 human embryonic kidney cells and purified by ultra-centrifugation through cesium chloride gradients. The virus titer was determined by plaque assay in 293 cells.
Infection Techniques
AMs were infected for 60 minutes at a multiplicity of infection (m.o.i.) of 150 plaque forming units (pfus)/cell in serum free RPMI. The medium-containing virus was then removed and replaced with complete media (RPMI with 5% fetal calf serum (FCS), 25 mM Hepes, 2 mM L-glutamine and 100 units/ml penicillin/streptomycin).
Western Immunoblotting
IKK
and I
B
were analyzed by Western Immunoblotting, while
immuno-precipitation was performed to analyze NIK expression. After 48 hours, AMs were removed from the culture plate using "Cell
Dissociation Solution" (Sigma, Poole, UK). Cytosolic and nuclear extracts were prepared as described by Whiteside and colleagues (44).
Protein was quantified by Bradford assay and 100 µg loaded for SDS/
PAGE separation on a 10% (wt/vol) polyacrylamide gel, before electrotransfer onto polyvinyl difluoride (PVDF) membranes (Millipore,
Bedford, MA).
-I
B
, IKK
, and IKK
mAbs (Santa Cruz Biotechnology, Santa Cruz, CA) were used as primaries, while the secondary
was a horseradish peroxidase-conjugated (HRP) donkey
-rabbit
(Amersham International, Oxford, UK). An
-FLAGM2-agarose affinity gel (Sigma, Poole, UK) was used for immunoprecipitation of
NIK proteins, with an
-NIK (Santa Cruz Biotechnology, Santa Cruz,
CA) and HRP-conjugated
-goat (Dako, Cambridge, UK) as the respective primaries and secondaries.
Electrophoretic Mobility-Shift Assay
Twenty-four hours after infection with the stated Adv construct, AMs
were treated with either TNF-
10 ng/ml or IL-1 10 ng/ml before being dissociated from the wells and the nuclear proteins extracted as
described by Dent and Latchman (45). The cells were lysed in hypotonic buffer (0.5% Nonidet P-40, 10 mM Hepes [pH 7.9], 10 mM KCL,
1 mM DTT, 2 mM PMSF, 30 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin) before the nuclei were harvested by centrifugation
(1,200 rpm for five minutes) and resuspended in a hypertonic extraction buffer (5 mM Hepes [pH 7.9], 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 M NaCl, 25% glycerol, 1 mM DTT, 2 mM PMSF, 30 µg/ml leupeptin, 10 µg/ml aprotinin, 10 µg/ml pepstatin). Samples were agitated for
60 minutes at 4° C before being centrifuged (12,000 rpm for 10 minutes), and the supernatant containing the nuclear proteins aspirated.
Protein concentration was quantified by Bradford assay and 20 µg run
on a 5% TBE gel with a [
-32P]-ATP labeled NF-
B consensus oligonucleotide (Promega, Madison, WI). The gels were dried onto filter
paper and retarded DNA complexes visualized using Hyperfilm (Amersham Pharmacia Biotech, Cambridge, UK). Competition and supershift assays were performed to confirm that the highlighted bands were
NF-
B. Competition assays involved incubating the nuclear extracts with
[
-32P]-ATP labeled NF-
B and either 100 × unlabeled NF-
B or
AP-1 (non-specific) oligonucleotides. For the supershift assays, nuclear proteins were incubated for two hours at 4° C with antibodies specific
to the known NF-
B components (p50, RelB, c-Rel and p65) before the
[
-32P]-ATP labeled NF-
B oligonucleotide was added.
Cytokine Analysis
Supernatants were harvested at 24 hours and centrifuged at 1,500 rpm. TNF-
, IL-6 and IL-8 production at 24 hours was analyzed by
sandwich enzyme-linked immuosorbent assay (ELISA) as previously described (32).
Statistical Methods
Cytokine production by Adv infected cells was expressed as a percentage of that produced by uninfected cells. The mean and standard deviation (SD) of percentage cytokine production by Adv-infected cells was then calculated relative to uninfected cells from the same specimen.
| |
RESULTS |
|---|
|
|
|---|
Selective Over-Expression of IKK
, NIK, and I
B
in AMs
The efficiency of Adv-mediated delivery of transgenes encoding IKK
and I
B
to primary AMs was assessed by western
immunoblotting. Low levels of NIK expression and the absence of a high affinity anti-NIK monoclonal requires the use
of immunoprecipitation for analysis. Figure 1 demonstrates the
cytosolic expression of the protein of interest 48 hours after infection with the stated Adv construct. Over-expression of (a)
NIK, (b) IKK
, and (c) I
B
was detected in AMs infected
with the AdvNIKwt and kd, AdvIKK
kd, and AdvI
B
constructs respectively. Endogenous NIK was undetected in uninfected and AdvGFP infected cells. Endogenous IKK
expression was unaffected by IKK
over-expression.
|
Over-Expression of IKK
kd and I
B
, but Not NIKkd, Inhibits
Constitutive NF-
B Activation in AMs
In contrast to normal AMs, there is significant constitutive
NF-
B activity in diseased AMs (9, 35, 46). To determine if cytoplasmic over-expression of IKK
kd, I
B
, and NIKkd would influence this constitutive NF-
B activity, electrophoretic
mobility-shift assay (EMSAs) were performed on the nuclear
extracts of uninfected, AdvGFP, AdvNIKkd, AdvIKK
kd, and
AdvI
B
infected AMs. Competition assays (Figure 2) indicated that the two bands are NF-
B specific with a subsequent
supershift assay confirming that the upper band (arrow) is the
p50/p65 heterodimer and the lower band represents unknown
NF-
B components (see online data supplement). NF-
B activity was inhibited by IKK
kd, and I
B
, but unaffected by
NIKkd and GFP over-expression.
|
Infection of AMs with AdvIKK
kd and AdvI
B
, but Not
AdvNIKkd, Inhibits Constitutive Cytokine Production
The data suggest that constitutive NF-
B dependent gene expression by AMs from patients with FA would be inhibited by
IKK
kd and I
B
, but not by NIKkd or GFP over-expression. To test this hypothesis, the constitutive production of
TNF-
, IL-6, and IL-8 by AMs, obtained from five consecutive BAL specimens that were either uninfected or infected
with the AdvGFP, AdvNIKkd, AdvIKK
kd, and AdvI
B
constructs, was analyzed (Figure 3). TNF-
production (n = 5, range = 401-1390 pg/ml) by AdvIKK
kd and AdvI
B
infected AMs was reduced to 34.1 ± 6.6% and 32.4 ± 11.1% of control, respectively, whereas TNF-
production by AdvNIKkd
infected cells was only minimally reduced to 84.5 ± 8.6% (Figure 3A). IL-6 production (n = 5, range = 432-3821 pg/ml) by
AdvIKK
kd and AdvI
B
infected AMs was reduced to 24.1 ± 8.2% and 26.1 ± 14.2% of control, respectively, whereas IL-6
production by AdvNIKkd infected cells was unaffected (98.0 ± 8.7%)(Figure 3B). IL-8 production (n = 5, range = 47,268-
6,0034 pg/ml) by AdvIKK
kd and AdvI
B
infected AMs
was reduced to 32.4 ± 9.4% and 22.4 ± 5.7% of control, respectively, whereas AdvNIKkd infection (86.4 ± 3.8%) had
minimal effect on chemokine production (Figure 3C). There
was no difference in either TNF-
, IL-6, or IL-8 production by
AdvGFP infected AMs relative to uninfected cells.
|
Over-Expression of IKK
kd and I
B
, but Not NIKkd, Inhibits
TNF-
Mediated NF-
B Activation in AMs
The data presented so far indicate that NF-
B activation in AMs
is IKK
, but not NIK, dependent. The in vivo stimuli involved in
this process are not, however, fully understood, and may involve cytokines (e.g., TNF-
) that have been shown in transformed cell lines to activate NF-
B via NIK dependent pathways (20, 47, 48).
To further define the role of NIK, IKK
, and I
B
in NF-
B activation, NF-
B activity was analyzed in TNF-
-treated AMs infected with AdvGFP, AdvNIKkd, AdvIKK
kd, or AdvI
B
.
Paired wells containing 4 × 106 AMs from a single BAL were infected with the stated Adv construct. Forty-eight hours later, one
well from each pair was treated with TNF-
10 ng/ml for 45 minutes before all cells were lysed and nuclear extracts prepared
(Figure 4). NF-
B activation in AdvGFP infected AMs following
treatment with TNF-
was largely inhibited by over-expression
of IKK
kd and I
B
, but not NIKkd.
|
Infection of AMs with AdvIKK
kd and AdvI
B
, but Not
AdvNIKkd, Inhibits Cytokine-induced IL-6 Production
The data indicate that cytokine-mediated NF-
B activation in
AMs requires a functional IKK
subunit, but not NIK. To further define the role of these two kinases in the activation of
NF-
B, IL-6 production by uninfected and AdvGFP, AdvNIKkd, AdvIKK
kd, or AdvI
B
infected AMs, treated
with either TNF-
or IL-1 from three to five consecutive FA
patients, was analyzed. There was no difference in IL-6 production by AdvGFP and AdvNIKkd infected AMs relative to
uninfected cells. In contrast, IL-6 production by AdvIKK
kd
and AdvI
B
infected AMs was substantially reduced (Table
1 and Figure 5). These results confirm that over-expression of
IKK
kd and I
B
, but not NIKkd, inhibits NF-
B-dependent proinflammatory gene transcription in primary AMs.
|
|
Because the molecular pathways involved in cytokine gene
transcription depend not only on the mechanism of cell activation, but also lineage (49-51), it was possible that the data obtained from AMs relating to the function of NIK, IKK
, and
I
B
are not applicable to other primary human cells. To investigate this possibility, identical studies were performed using
human umbilical vein endothelial cells (HUVECs) that, like
diseased AMs, are permissive to Adv infection. Again, IL-6
production by AdvIKK
kd and AdvI
B
, but not AdvGFP
or AdvNIKkd infected cells, was reduced relative to uninfected cells (see online data supplement).
NF-
B Activation in AMs Secondary to NIKwt Over-Expression
Is Inhibited by Coinfection with AdvNIKkd, AdvIKK
kd,
and AdvI
B
The failure to demonstrate an absolute requirement for NIK in
constitutive and cytokine mediated NF-
B activation suggests the presence of an alternative mitogen-activated protein-3 kinase (MAP3K), able to degrade I
B. Alternatively, despite
previous studies demonstrating that the substitution of lysine
429/430 for alanine within the NIK ATP binding site produced
a kinase defective protein in both primary cells and transformed
cell lines (20, 38), it was possible that this protein was functional in AMs and HUVECs. AdvNIKkd infected AMs were
also treated with zymosan, lipopolysacharide (LPS), and
-CD45
mAb in an attempt to identify a stimulus for NF-
B activation
inhibited by NIKkd over-expression, and therefore establish
the kinase-defective nature of NIKkd in these cells. TNF-
production by AdvNIKkd infected AMs was not reduced relative
to uninfected or AdvGFP infected AMs (results not shown),
failing to confirm that the NIKkd was kinase defective. Transfection of NIKwt into transformed cell lines has been shown
to activate NF-
B-dependent gene transcription (52, 53). In
preliminary studies, Adv-mediated delivery of NIKwt to AMs
was also shown to be a potent stimulus for NF-
B dependent
gene expression, with a progressively increasing titer of AdvNIKwt resulting in a dose-dependent augmentation of IL-6 production (see online data supplement). It was possible that this stimulus for NF-
B activation would be inhibited by coexpression of NIKkd.
To validate data obtained from studies involving coinfection
of AMs with two different Adv constructs, it was first necessary to demonstrate that coexpression of two virally encoded proteins was possible. Western immunoblotting and immunoprecipitation was performed on the cytosolic extracts of AMs 48 hours after coinfection with AdvNIKwt and either AdvGFP,
AdvNIKkd, AdvIKK
kd, or AdvI
B
. Over-expression of two
virally encoded proteins was demonstrated in AMs coinfected with
AdvNIKwt, AdvNIKkd, AdvIKK
kd, and AdvI
B
(Figure 6).
|
EMSAs were performed on the nuclear extracts of AMs
that were uninfected, infected with GFP or AdvNIKwt alone, or
coinfected with the stated Adv constructs (Figure 7). As expected, there was augmented NF-
B activity in cells infected
with AdvNIKwt alone relative to uninfected and AdvGFP infected cells. There was no difference in the NF-
B activity of
AMs infected with AdvNIKwt alone compared with those
coinfected with AdvNIKwt and AdvGFP, indicating that the
higher virus titer per se (total m.o.i. 200 pfus) had little effect
on NF-
B activity. NF-
B activity in AMs coinfected with
AdvNIKwt and either AdvNIKkd, AdvIKK
kd, or AdvI
B
was similarly reduced indicating that when the stimulus was
NIKwt, NIKkd was as effective as IKK
kd and I
B
in inhibiting NF-
B activity.
|
IL-6 Production by AMs Activated by NIKwt Over-Expression Is
Inhibited by Coinfection with AdvNIKkd, AdvIKK
kd,
and AdvI
B
To provide further evidence that the NIK encoded by the
AdvNIKkd construct was kinase defective, IL-6 production by
AMs coinfected with AdvNIKwt and either AdvGFP, AdvNIKkd, AdvIKK
kd, or AdvI
B
was analyzed. Augmented
IL-6 production was demonstrated in the AdvNIKwt infected
AMs relative to the uninfected (negative control) and AdvGFP
infected cells (positive control) (see online data supplement).
The mean and SD of percentage IL-6 production by cells coinfected with the stated Adv construct was calculated relative to
cells infected with AdvNIKwt alone. IL-6 production by AMs
coinfected with AdvNIKwt and AdvGFP did not significantly differ from cellular preparations infected with AdvNIKwt
alone, indicating that increased viral titer per se had little effect on IL-6 gene expression (Figure 8). In contrast, IL-6 production by AMs coinfected with AdvNIKwt and either AdvNIKkd, AdvIKK
kd, or AdvI
B
was reduced to 23.7 ± 13.9%, 24.1 ± 4.9%, and 22.1 ± 7.2%, respectively (range: 4,832-6,943pg/ml).
Again, identical studies performed using HUVECs produced
similar results, with AdvNIKkd, AdvIKK
kd, or AdvI
B
coinfection resulting in inhibition of IL-6 gene expression (see
online data supplement).
|
| |
DISCUSSION |
|---|
|
|
|---|
In this study, we have investigated the molecular mechanisms
of NF-
B activation in primary AMs using a novel Adv-mediated gene delivery system. Upregulation of the CAR,
v, and
v
5 integrins on AMs obtained from patients with fibrosing
lung diseases allows efficient Adv infection and analysis of
molecular signaling pathways (35). Using Adv constructs encoding a NIK and IKK
subunit previously determined to be
kinase defective (20, 38, 39), we demonstrated that constitutive and cytokine induced NF-
B activation by AMs requires
a catalytically active IKK
subunit, but not NIK dependent signaling.
Adv mediated over-expression of I
B
in primary human
macrophages inhibits nuclear translocation of NF-
B and
IL-6 production, providing direct evidence that NF-
B activation is required for cytokine gene transcription (33, 35, 43, 54).
The observation that Adv mediated over-expression of IKK
kd also inhibits NF-
B activation and cytokine production
establishes a similar requirement for IKK
in the process of
NF-
B activation within primary AMs. The current model of
NF-
B activation is based largely on studies involving cell
lines and transgenic mice that die in utero and envisages that
IKK
phosphorylation is required for cytokine mediated I
B
degradation (24, 25). Some studies have suggested, however, that the role of IKK may depend on cell lineage and the state of cellular differentiation (22, 55). For example, Fischer and
coworkers reported that LPS induced activation of IKK in
THP-1 monocytes occurred primarily as a result of IKK
phosphorylation, but TNF-
and IL-1 treatment resulted in rapid
IKK
phosphorylation with only minimal alteration in IKK
activity (55). As the mechanism NF-
B activation in FA is
likely to involve TNF-
and IL-1 (4, 56), it was possible that a
functional IKK
was not required for I
B
degradation in
AMs. The data presented in this study does, however, support
this existing model of IKK function, indicating that the different mechanisms of IKK activation observed in macrophage cell lines are not of functional significance in primary AMs. We have, however, noted that LPS induced NF-
B activation
in fibroblasts and peripheral blood monocytes is only minimally affected by IKK
kd over-expression (unpublished observations), suggesting that there could be variation in IKK
function between different primary macrophages. This study
is important because it confirms that IKK
is required for
NF-
B activation in primary AMs and suggests that Adv-
mediated transgene delivery can be used to investigate possible differential IKK function.
The failure of NIKkd to inhibit TNF and IL-1 mediated
NF-
B activation was unexpected as, when delivered to HeLa
and A293 cell lines by transfection and Adv constructs, this
protein has been shown to effectively inhibit NF-
B activation
(20, 38). The observation that constitutive and cytokine mediated NF-
B dependent gene expression in AMs does not require NIK, highlights the limitations of studies involving cell
lines in predicting disease specific molecular signaling pathways within primary human cells. NIK was originally identified as the critical IKK kinase required for cytokine mediated
NF-
B activation by Malinin and coworkers, who demonstrated that in 293-EBNA cells over-expression of the same
NIK used in this study ablated TNF-
-induced NF-
B activation (20). A number of subsequent studies involving cell lines
and utilizing NIKkd constructs also demonstrated a similar requirement for NIK in NF-
B-dependent gene transcription
(47, 48, 57). Recent studies involving the aly/aly mouse that
expresses a NIK with a single amino acid substitution within
the C-terminal interaction domain, preventing association with
TRAF2, have, however, called into question the applicability
of this data to the molecular regulation of NF-
B within primary cells. The aly/aly phenotype is characterized by disorganized thymic and splenic structure, absent lymph nodes, and
humoral immunodeficiency that can be completely reversed by
NIKwt expression (30). Despite expressing a NIK that does
not recognize TRAF2 and 6, the aly/aly mouse and embryonic fibroblasts still activate NF-
B in response to TNF-
and LPS, suggesting that there is an alternative MAP3K capable of activating IKK. It is possible that the mitogen activated protein
kinase/ERK kinase kinase (MEKK1) is the alternative MAP3K
involved in cytokine mediated NF-
B activation (Figure 9).
MEKK1 is a component of the stress activated c-Jun N-terminal
kinase (JNK) pathway that has been shown in one study to directly activate IKK (58). The observation that chimeric TRAF2
proteins that are unable to interact with NIK retain the ability
to activate IKK provides further evidence that there are NIK-independent mechanisms of NF-
B activation (59). Our study
establishes that in primary AMs, NIK-independent mechanisms of IKK activation are functionally important and indicates that targeted inhibition of NIK is unlikely to reduce
NF-
B dependent gene expression.
|
There is mounting evidence that NF-
B activation in AMs is
important in the pathogenesis of many pulmonary diseases (7, 8). Elevated levels of NF-
B have been detected in AMs obtained from patients with ARDS (13), but not from cells obtained from healthy volunteers (9). It has also been reported
that in vitro exposure of AMs to asbestos fibers increases
NF-
B activity at sites within the promoter region of the IL-6
and IL-8 genes (60). Corticosteroids inhibit NF-
B activation
and highlight the central role of this transcription factor in the
pathogenesis of pulmonary inflammation. Corticosteroids inhibit NF-
B activation through upregulation of I
B
gene expression and an interaction between the ligand bound glucocorticoid receptor and NF-
B (61, 62). It has been proposed
that targeted inhibition of NF-
B activation may provide the
immunosuppressive benefits of corticosteroids, while avoiding
many of the unwanted side effects. The data presented in this
study indicates that inhibition of the kinase cascade above the
level of IKK is unlikely to result in effective inhibition of
NF-
B-dependent gene expression. Our study indicates that
strategies preventing IKK
phosphorylation or degradation of
I
B
would be more likely to attenuate the constitutive and cytokine mediated activation of NF-
B in AMs.
Until recently, thoracic molecular research has focused on
the role of the eosinophil and lymphocyte in the pathogenesis
of airway-centered inflammation. The recognition by the World
Health Organization that COPD will become the third most
common cause of death in industrialized nations by 2020 (63)
has, however, led to increased interest in the molecular mechanisms of this disease, which involves activation of AMs in the
distal airspaces. Our study highlights the potential of Adv-mediated transgene delivery as a technique for investigating
dysregulated AM function in pulmonary disease. Using Adv-mediated gene delivery, we have made some potentially, clinically relevant observations regarding NF-
B regulation in AMs. We have also achieved more than 95%
-galactosidase
reporter gene expression in freshly prepared AMs from patients with COPD and ARDS (unpublished observations). It
is likely, therefore, that the inflammatory process in COPD and
ARDS also upregulates the CAR and
v integrins and will
permit the application of this technique to the investigation of
the molecular mechanisms of inflammation in these conditions.
In this study, we have established in AMs that NIK is not
required for constitutive or cytokine-mediated activation of IKK, and that IKK
is the critical IKK subunit necessary for NF-
B activation. The requirement for a functional IKK
in cytokine-mediated NF-
B activation within primary AMs was predicted
by earlier studies involving cell lines and knockout mice. We
found no evidence that the different patterns of IKK
phosphorylation demonstrated in macrophage cell lines are of functional significance in primary AMs. In contrast, the failure of
NIKkd overexpression to inhibit NF-
B activation did not support the existing model of NIK function and indicates that
there are important differences in the regulation of NF-
B between primary cells and transformed cell lines. The data suggest that AMs possess an alternative IKK kinase capable of
activating NF-
B. In contrast to studies involving cell lines, we
determined that in primary AMs and HUVECs, IKK, not NIK,
is the point where the pathways responsible for NF-
B activation converge. This study highlights the potential value of
Adv mediated gene delivery as a tool to investigate the disease specific mechanisms of NF-
B regulation in FA.
| |
Footnotes |
|---|
Correspondence and requests for reprints should be addressed to Dr. Matthew Conron, Department of Respiratory Medicine, St. Vincents Hospital (Melbourne), 41 Victoria Parade, PO Box 2900 Fitzroy, Victoria, 3065, Australia. E-mail: conronm{at}svhm.org.au
(Received in original form July 12, 2001 and accepted in revised form January 7, 2002).
This article has an online data supplement, which is accessible from this issue's table of contents online at www.atsjournals.orgAcknowledgments: Supported by the ARC, Wellcome, and BBR Medical Education.
| |
References |
|---|
|
|
|---|
1. Agostini C, Semenzato G. Immunology of idiopathic pulmonary fibrosis. Curr Opin Pulm Med 1996; 2: 364-369 . [Medline]
2.
Kamp DW,
Weitzman SA.
The molecular basis of asbestos induced lung
injury.
Thorax
1999;
54:
638-652
3. Ward PA, Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998;157(Suppl 4):S123-S129.
4. Coker RK, Laurent GJ. Pulmonary fibrosis: cytokines in the balance. Eur Respir J 1998; 11: 1218-1221 [Abstract].
5. Vaillant P, Menard O, Vignaud JM, Martinet N, Martinet Y. The role of cytokines in human lung fibrosis. Monaldi Arch Chest Dis 1996; 51: 145-152 [Medline].
6. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980; 35: 171-180 [Medline].
7.
Blackwell TS,
Christman JW.
The role of nuclear factor-kappa B in cytokine gene regulation.
Am J Respir Cell Mol Biol
1997;
17:
3-9
8. Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy [see comments]. Intensive Care Med 1998; 24: 1131-1138 [Medline].
9. Farver CF, Raychaudhuri B, Buhrow LT, Connors MJ, Thomassen MJ. Constitutive NF-kappaB levels in human alveolar macrophages from normal volunteers. Cytokine 1998; 10: 868-871 [Medline].
10.
Janssen YM,
Barchowsky A,
Treadwell M,
Driscoll KE,
Mossman BT.
Asbestos induces nuclear factor kappa B (NF-kappa B) DNA-binding
activity and NF-kappa B-dependent gene expression in tracheal epithelial cells.
Proc Natl Acad Sci USA
1995;
92:
8458-8462
11. Janssen YM, Driscoll KE, Howard B, Quinlan TR, Treadwell M, Barchowsky A, Mossman BT. Asbestos causes translocation of p65 protein and increases NF-kappa B DNA binding activity in rat lung epithelial and pleural mesothelial cells. Am J Pathol 1997; 151: 389-401 [Abstract].
12.
Barnes PJ.
Chronic obstructive pulmonary disease.
N Engl J Med
2000;
343:
269-280
13. Schwartz MD, Moore EE, Moore FA, Shenkar R, Moine P, Haenel JB, Abraham E. Nuclear factor-kappa B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit Care Med 1996; 24: 1285-1292 [Medline].
14. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol 1994; 10: 405-455 .
15. Baldwin AS Jr.. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-683 [Medline].
16.
Brown K,
Gerstberger S,
Carlson L,
Franzoso G,
Siebenlist U.
Control
of I kappa B-alpha proteolysis by site-specific, signal-induced phosphorylation.
Science
1995;
267:
1485-1488
17. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-785 [Medline].
18. Yaron A, Hatzubai A, Davis M, Lavon I, Amit S, Manning AM, Andersen JS, Mann M, Mercurio F, Ben-Neriah Y. Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature 1998; 396: 590-594 [Medline].
19. Yaron A, Gonen H, Alkalay I, Hatzubai A, Jung S, Beyth S, Mercurlo F, Manning AM, Clechanover A, Ben-Neriah Y. Inhibition of NF-kappa-B cellular function via specific targeting of the I-kappa-B-ubiquitin ligase. EMBO J 1997; 16: 6486-6494 [Medline].
20. Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature 1997; 385: 540-544 [Medline].
21. Regnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M. Identification and characterization of an IkappaB kinase. Cell 1997; 90: 373-383 [Medline].
22. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB [see comments]. Nature 1997; 388: 548-554 [Medline].
23. Cohen L, Henzel WJ, Baeuerle PA. IKAP is a scaffold protein of the IkappaB kinase complex. Nature 1998; 395: 292-296 [Medline].
24.
Li J,
Peet GW,
Pullen SS,
Schembri-King J,
Warren TC,
Marcu KB,
Kehry MR,
Barton R,
Jakes S.
Recombinant IkappaB kinases alpha
and beta are direct kinases of Ikappa Balpha.
J Biol Chem
1998;
273:
30736-30741
25.
Li ZW,
Chu W,
Hu Y,
Delhase M,
Deerinck T,
Ellisman M,
Johnson R,
Karin M.
The IKKbeta subunit of IkappaB kinase (IKK) is essential
for nuclear factor kappaB activation and prevention of apoptosis.
J
Exp Med
1999;
189:
1839-1845
26.
Hu Y,
Baud V,
Delhase M,
Zhang P,
Deerinck T,
Ellisman M,
Johnson R,
Karin M.
Abnormal morphogenesis but intact IKK activation in
mice lacking the IKKalpha subunit of IkappaB kinase [see comments].
Science
1999;
284:
316-320
27.
Zandi E,
Chen Y,
Karin M.
Direct phosphorylation of IkappaB by
IKKalpha and IKKbeta: discrimination between free and NF-kappaB-bound substrate.
Science
1998;
281:
1360-1363
28.
Verma IM,
Stevenson JK,
Schwarz EM,
Van Antwerp D,
Miyamoto S.
Rel/NF-kappa B/I kappa B family: intimate tales of association and
dissociation.
Genes Dev
1995;
9:
2723-2735
29. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994; 76: 959-962 [Medline].
30. Shinkura R, Kitada K, Matsuda F, Tashiro K, Ikuta K, Suzuki M, Kogishi K, Serikawa T, Honjo T. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-kappa b-inducing kinase. Nat Genet 1999; 22: 74-77 [Medline].
31.
Yin L,
Wu L,
Wesche H,
Arthur CD,
White JM,
Goeddel DV,
Schreiber RD.
Defective lymphotoxin-beta receptor-induced NF-kappaB transcriptional activity in NIK-deficient mice.
Science
2001;
291:
2162-2165
32.
Matsushima A,
Kaisho T,
Rennert PD,
Nakano H,
Kurosawa K,
Uchida D,
Takeda K,
Akira S,
Matsumoto M.
Essential role of nuclear factor
(NF)-kappaB-inducing kinase and inhibitor of kappaB (IkappaB) kinase alpha in NF-kappaB activation through lymphotoxin beta receptor, but not through tumor necrosis factor receptor I.
J Exp Med
2001;
193:
631-636
33.
Bondeson J,
Foxwell B,
Brennan F,
Feldmann M.
Defining therapeutic
targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but
spares anti-inflammatory mediators.
Proc Natl Acad Sci USA
1999;
96:
5668-5673
34.
Hayes AL,
Smith C,
Foxwell BM,
Brennan FM.
CD45-induced tumor
necrosis factor alpha production in monocytes is phosphatidylinositol
3-kinase-dependent and nuclear factor-kappaB- independent.
J Biol
Chem
1999;
274:
33455-33461
35.
Conron M,
Bondeson J,
Pantelidis P,
Beynon HLC,
Feldmann M,
duBois RM,
Foxwell BMJ.
Alveolar macrophages and T cells from
sarcoid, but not normal lung are permissive to adenovirus infection
and allow analysis of NF-
B dependent signaling pathways.
Am J
Respir Cell Mol Biol
2001;
25:
141-149
36.
Bergelson JM,
Cunningham JA,
Droguett G,
Kurt-Jones EA,
Krithivas A,
Hong JS,
Horwitz MS,
Crowell RL,
Finberg RW.
Isolation of a
common receptor for Coxsackie B viruses and adenoviruses 2 and 5.
Science
1997;
275:
1320-1323
37. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319 [Medline].
38.
Smith C,
Adreakos E,
Crawley JB,
Brennan FM,
Feldmann M,
Foxwell BMJ.
NF-
B inducing kinase is dispensable for activation of NF-
B in
inflammatory settings but essential for LT
R activation of NF-
B in
primary human fibroblasts.
J Immunol
2001;
167:
5895-5903
39.
Oitzinger W,
Hofer-Warbinek R,
Schmid JA,
Koshelnick Y,
Binder BR,
de Martin R.
Adenovirus-mediated expression of a mutant IkappaB
kinase 2 inhibits the response of endothelial cells to inflammatory
stimuli.
Blood
2001;
97:
1611-1617
40. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990;141:S169-S202.
41. King TE Jr,, Costabel U, Cordier J-F, DoPico GA, duBois RM, Lynch D, Lynch JP III,, Myers J, Panos R, Raghu G, et al . Idiopathic Pulmonary Fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med 2000; 161: 646-664